06.09.21

Outlook Therapeutics Completes Patient Dosing in Phase 3 NORSE TWO Trial for Wet AMD

Source: Outlook Therapeutics

03.31.21

Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenava

Source: Outlook Therapeutics

02.11.21

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/Lytenava (Bevacizumab-vikg)

Source: Outlook Therapeutics

11.03.20

Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseases

Source: Outlook Therapeutics

10.13.20

Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMD

Source: Outlook Therapeutics

09.30.20

Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration

Source: Outlook Therapeutics

07.07.20

Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenava

Source: Outlook Therapeutics

12.05.18

Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategy

Source: Outlook Therapeutics

View more stories